EU Formally Revokes Tavneos Marketing Authorization as Unreliable Pivotal Trial Data Reshape Drug’s Fate
From the recommendation to revoke authorization in June to the final decision, Tavneos has now been listed by the EU as a medicine whose authorization is no longer valid. At the heart of the controversy is not merely an analytical error, but the reassessment of patient data after unblinding, which pushed results that had originally failed to demonstrate superiority past the threshold for statistical significance.